Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical (RARE) click here.